Testing insulin resistance in multiple system atrophy
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 30 years old
- If you have MSA: your doctor has diagnosed “possible” or “probable” MSA
- You can give written consent (or you have the legal ability to do so)
- You are covered by the national health system
- You do not have diabetes
- You can safely have an MRI (no MRI contraindications)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests a new antibody drug that targets a protein linked to multiple system atrophy (MSA). It aims to see if the drug is safe and may slow the disease, for people recently diagnosed.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This study collects data from people with Parkinson's disease or multiple system atrophy (MSA) to better understand these conditions. You will have blood, saliva, optional spinal fluid tests, and brain scans (MRI, PET/SPECT).
This study looks at how medical decisions are made for people with multiple system atrophy (MSA). It includes both people with MSA and their unpaid caregivers who live in Austria and speak German. Participants and caregivers will share their experiences through online interviews to help improve future care.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.